Phytochemical Profile and Chemosensitizing Anticancer Activity of Mitragyna speciosa and Mitragynine

Why it matters

First evidence that kratom extract and mitragynine act as chemosensitizers, enhancing the effectiveness of standard chemotherapy drugs like cisplatin and doxorubicin against multiple cancer cell lines, opening potential therapeutic pathways.

The big picture

While kratom alkaloids have been studied for pain and opioid-like effects, this research reveals a novel mechanistic property: both crude kratom extract and purified mitragynine suppress cancer cell proliferation AND synergistically enhance chemotherapy efficacy. The effect appears strongest against cervical cancer (HeLa) and cholangiocarcinoma cells.

Key findings

• Kratom extract and mitragynine independently suppressed cancer cell proliferation in A549, KKU213C, and HeLa cell lines in concentration- and time-dependent manner
• Mitragynine displayed greater potency than crude extract, especially against cholangiocarcinoma
• Synergistic cytotoxic effects observed when combined with standard chemotherapy agents
• Cytotoxicity correlated with reduced expression of anti-apoptotic protein BCL-2
• Anticancer effects suggest chemosensitizing rather than primary anti-cancer mechanisms

What they say

The authors conclude: "The results show that Mitragyna speciosa extract and mitragynine are chemosensitizers that could make standard chemotherapy work better. Additional research is necessary to clarify the molecular mechanisms involved and to confirm these effects in vivo."

Bottom line

**Kratom alkaloids may enhance cancer drug efficacy in vitro—if confirmed in vivo, this could represent a novel adjunctive cancer therapy approach, though human studies are years away.**